Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IDH-305 is an orally available, mutation-selective, and brain-penetrant IDH1 inhibitor targeting the IDH1 (R132) mutation. IDH-305 is 200-fold more selective for mutant IDH1 isoforms than wild type with IC50s of 27 nM,28 nM and 6.14 nM for IDH1R132H, IDH1R132C and IDH1WT, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 52.00 | |
5 mg | In stock | $ 128.00 | |
10 mg | In stock | $ 178.00 | |
25 mg | In stock | $ 369.00 | |
50 mg | In stock | $ 558.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 139.00 |
Description | IDH-305 is an orally available, mutation-selective, and brain-penetrant IDH1 inhibitor targeting the IDH1 (R132) mutation. IDH-305 is 200-fold more selective for mutant IDH1 isoforms than wild type with IC50s of 27 nM,28 nM and 6.14 nM for IDH1R132H, IDH1R132C and IDH1WT, respectively. |
Targets&IC50 | IDH1 (R132C):28 nM, IDH1 (R132H):27 nM, IDH1 (WT):6.14 μM |
In vitro | IDH-305 suppresses HCT116-IDH1R132H /- cells (IC50 of 24 nM)[1]. |
In vivo | P.o. administration of 30-300 mg/kg IDH-305 twice daily for 21 days suppresses 2-HG production and 2-HG-dependent tumor growth of an IDH1 mutant PDX melanoma model [1]. |
Molecular Weight | 490.45 |
Formula | C23H22F4N6O2 |
CAS No. | 1628805-46-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (203.90 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IDH-305 1628805-46-8 Metabolism Dehydrogenase IDH 305 Isocitrate Dehydrogenase (IDH) IDH305 Inhibitor inhibit inhibitor